Rahul D. Ballal, Director at Enliven Therapeutics, Inc. (ELVN), sold 6,970 shares at $19.15 ($133K) on 2024-04-04, disclosed to the SEC on 2024-04-08.
Scheduled sale ($133k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.15 | 3,485 | $67K | 50.0% |
| 2 | $19.15 | 3,485 | $67K | 50.0% |
| Total | $19.15 avg | 6,970 | $133K | 100% |
| Filing → |
| ELVN | SELL | 2024-04-12 | $1.6M | — | Filing → |
| ELVN | SELL | 2024-04-03 | $124K | — | Filing → |
| ELVN | SELL | 2024-03-22 | $509K | — | Filing → |